Balancing risks and rewards

How to optimize busulfan monitoring for safer, more cost-effective care

The alkylating agent busulfan has great utility for patients undergoing hematopoietic cell transplant (HCT). Typically combined with cyclophosphamide or fludarabine/clofarabine, busulfan can help kill cancer cells, enable new blood stem cells to grow in patients’ bone marrow, and prevent rejection of newly transplanted cells.

Properly calibrating busulfan, however, can be a dangerous challenge. Too little may result in rejection of new stem cells, while too much can cause regimen-related toxicity that may result in a host of serious disorders.

Download our new white paper to learn how combining therapeutic drug monitoring (TDM) with model-informed precision dosing (MIPD) can help achieve optimal drug exposures across a variety of populations.

Download your copy now!

Get a quote

Get a free quote now.

Thank you! Your message has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.